Status:
COMPLETED
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Lead Sponsor:
Pfizer
Conditions:
Renal Cell Cancer
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
Eligibility Criteria
Inclusion
- For the characteristic group:
- Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision \[ICD\]-10:64) during 01 January 2010 and 31 December 2021
- For the mRCC group:
- ICD-10 diagnosis code for metastasis (C77\*-C79\*), or
- American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients
- Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease
- Initiation of treatment for mRCC
Exclusion
- For the characteristic group:
- Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)
- Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021
- For the mRCC group:
- Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010)
- Patients without treatment for mRCC
Key Trial Info
Start Date :
May 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 8 2022
Estimated Enrollment :
1112 Patients enrolled
Trial Details
Trial ID
NCT05363072
Start Date
May 2 2022
End Date
June 8 2022
Last Update
October 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Finland
Helsinki, Finland, 00330